Standard operating procedure

Similar documents
Standard operating procedure

Standard operating procedure

Standard operating procedure

Standard operating procedure

Work instructions. 1. Changes since last revision. 2. Records. 3. Instructions. Documents needed for this WIN

Standard operating procedure

Lead Author Approver Effective Date: 13-MAR-13 Name: Ana Rodriguez Sanchez Review Date: 13-MAR-16

All external requests for access to information as well as their responses are entered into the Queries database.

Standard operating procedure

Standard operating procedure

All the documents related to the EU-RMP Annex 1 activities are stored at the following locations:

Standard operating procedure

Title: Handling of Art. 29(1) referrals to the CMDh (60 day procedure) by the CMDh secretariat (incl. Article 13 referrals for variations)

The WIN applies to the Vet Applications team in the Veterinary Regulatory and Organisational Support service (V-VM-ROS).

Applies to: SA Administrative Assistant, SAWP Scientific Secretary and SA secretarial team in Scientific Advice Section

This is the production release of the second iteration of EudraCT 8.1. It includes the following main functional changes:

Mock-ups checklist - Guidance for checking mock-ups

Chapter 5: Extended EudraVigilance Product Report Acknowledgement Message

European Medicines Agency Standard Operating Procedure

Standard operating procedure

SUBMISSION OF COMMENTS ON Guideline on Real Time Release Testing (formerly Guideline on Parametric Release) Draft

User guide on how to generate PDF versions of the product information - veterinary

How to send submissions via the Web Client

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE ON REQUIREMENTS FOR PLASMA MASTER FILE (PMF) CERTIFICATION

EMA esubmission Gateway and Web Client: Questions and answers on Veterinary Applications

Process description for managing duplicates in the context of the Medical Literature Monitoring (MLM) service

IRIS Quick guide to the portal for Orphan Industry users

esubmission Gateway and Web Client Training on the use of XML delivery files for Veterinary submissions

PSUR Repository and the EU single assessment

Multinational assessment teams

EMA procedural updates

Guidance for the format and content of the final study report of non-interventional post-authorisation safety studies

Guidance for submission and validation of electronic declaration of interests and electronic curriculum vitae

extended EudraVigilance Medicinal Product Dictionary (XEVMPD) Step-by-Step Guide

Title: Key activities when screening the electronic Reaction Monitoring Reports (ermrs) for new signals

esubmission Gateway Web Client

3 September

On-boarding of users to SPOR data services

PSUR Repository Implementation Plan

Management of RMP for CAPs in postauthorisation

Cover note on XEVMPD substance controlled vocabulary following the quality control exercise

ENCePP Code of Conduct Implementation Guidance for Sharing of ENCePP Study Data

Standard Operating Procedure. SOP full title: Sponsor processes for reporting Suspected Unexpected Serious Adverse Reactions

September 2015 Ginas Meeting Highlights

Date: May 19, Dear Dr. Domingo,

CMD(v)/BPG/006. BEST PRACTICE GUIDE For. Type II Variations. Edition 00. Edition date:

User Guidance for National Competent Authorities for PSUR Repository

STANDARD OPERATING PROCEDURE SOP 815. Clinical Data Management System LOCKING AND UNLOCKING THE DATABASE. Joint Research Office

EudraVigilance Release Notes v.1.13

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

EudraVigilance Components & Functionality Introduction

VARIATION FILING PROCEDURE IN EUROPE: A COMPLETE REVIEW

Supersedes Division Name Revision No. 00 Export Division Page No. 1 of 5

BEST PRACTICE GUIDE for The classification of unforeseen variations

Submissions to the PSUR Repository using EMA Gateway/Web Client

esubmissions Web UI Release Notes

List of nationally authorised medicinal products

Comments received from public consultation on good pharmacovigilance practices (GVP)

Welcome to the portal. We are very pleased for your interest in our vacancies.

Isabella Marta, Head of Marketing Authorization Department Italian Medicines Agency

EUROPEAN MEDICINES AGENCY (EMA) CONSULTATION

Citrix Remote Access

EMA Common Repository: Questions and answers relating to practical and technical aspects of the implementation

esubmissions Web UI Release Notes

extended EudraVigilance Medicinal Product Report Message (XEVPRM) Step-by-Step Guide

PSUR Repository Interactive Q&A

SOP-QA-32 V2. Document History Version Description of update Date Effective 1 Change of number for Q-Pulse

IRIS Quick guide to registration

BEST PRACTICE GUIDE for Type IB Variations. CMD(v)/BPG/005. Edition 00. Edition date: Implementation date:

ehealth Network ehealth Network Governance model for the ehealth Digital Service Infrastructure during the CEF funding

Version Control of Study Specific Documents

BEST PRACTICE GUIDE. For Type IB Variations. CMDv/BPG/005 Edition 05. Edition date: 10 April 2015

STANDARD OPERATING PROCEDURE

Procedure for Member State registration in the authorisation system SAAS

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

eaf Release Notes Table of Contents Version (Release Date: 13/07/2018)... 7 Version (Release Date: 16/02/2018)...

Guidance for registration with EudraVigilance Veterinary

Session 4. Workshop on the implementation of ISO standard for ICSRs. Testing with EMA new process

Q&A QP Declaration. Table of contents

MEDICAL DEVICES REGULATIONS 2002: REGULATIONS 19 and 30 FORM RG2

Dated 3 rd of November 2017 MEMORANDUM OF UNDERSTANDING SIERRA LEONE NATIONAL ehealth COORDINATION HUB

ERMS Folder Development and Access Process

IOGP. Supplementary Procedure for Development and Maintenance of ISO Standards as an ISO Liaison Member. Approved

Pre-notification check for type IB Variations 1

eaf Release Notes The most recent release appears first. Table of Contents Version (Release Date: 04/02/2019)... 7

extended EudraVigilance Medicinal Product Dictionary (XEVMPD) e-learning

Measures for Article 57 Data Quality Assurance

Global Wind Organisation CRITERIA FOR THE CERTIFICATION BODY

University staff and student broadcast policy. Overview. Scope. Related Documents

Departmental Policy Departmental Procedure Instructions/Forms. UCVM Diagnostic Services Unit Document Control Procedure

FedRAMP Initial Review Standard Operating Procedure. Version 1.3

Monitoring of Scientific Literature

Vaccine data collection tool Oct Functions, Indicators & Sub-Indicators

Notification to amend firm details

RMS & OMS Industry on-boarding to SPOR Webinar with Industry Change Liaisons

Variations in ectd format Q&A document

Connected Health Principles

PMS Iteration 1: analysis of the data efforts & value results and recommendation on the scope

To update firm name and trading names, website address, accounting reference date, auditors, locum, contacts and addresses.

Certification rules for the mark

Transcription:

Standard operating procedure Title: Sampling and testing of centrally authorised products Reports circulation and follow-up procedure Status: PUBLIC Document.: SOP/INSP/2011 Lead author Approver Effective date: 13-MAY-11 Name: Katalin Almasi Name: Fergus Sweeney Review date: 13-MAY-14 Signature: On file Signature: On file Supersedes: SOP/INSP/2011 (01-OCT-07) Date: 29-APR-11 Date: 29-APR-11 TrackWise record.: 2748 1. Purpose To establish a procedure for the circulation of CAP testing reports issued by the EDQM as part of the sampling and testing programme, and for the organisation and/or coordination of follow-up actions. 2. Scope This SOP applies to the Compliance and Inspection Sector only, and should be read in conjunction with the documents listed under section 6. 3. Responsibilities It is the responsibility of each Head of Sector to ensure that this procedure is adhered to within their own sector. The responsibility for the execution of a particular part of this procedure is identified in the right-hand column of section 9. 4. Changes since last revision Major revision of the SOP and update to reflect the organisational changes in the agency as well as a new corporate identity. 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)207 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union European Medicines Agency, 2011. Reproduction is authorised provided the source is ackwledged.

5. Documents needed for this SOP Template for checklist for validation of draft CAP reports (X:\Templates\Others\Compliance and Inspection\S&T\Checklist for validation draft CAP testing reports) Template for Eudralink messages, for the transmission of CAP Testing Report to the Marketing Authorisation Holder (X:\Templates\Others\Compliance and Inspection\S&T\CAP Testing Report to MAH) Template for Eudralink messages, for the transmission of CAP Testing Report to the Rapporteurs (X:\Templates\Others\Compliance and Inspection\S&T\ CAP Testing Report to Rapps) Template for Reply Sheet (X:\Templates\Others\Compliance and Inspection\S&T\Reply Sheet) 6. Related documents Sampling and Testing of Centrally Authorised Products - Objectives and description of the Programme (EMA/INS/S&T/5291/2005) Operational Units/Inspections/Samptest/c_Procedures/m_General Procedures SOP/INSP/2010 Sampling and testing of centrally authorised products SOP/INSP/2018 Dealing with Reports of Defective Medicinal Products 7. Definitions P-CI: CTR: Compliance and Inspection Sector in the Patient Health Protection Unit CAP testing report (document issued by EDQM for each product tested, containing results of the tests carried out) DREAM: EDQM: GMP: P-CI coordinator: MAH: OOS: PTL: PTMQ: Document Records Electronic Archive Management European Directorate for the Quality of Medicines and HealthCare Good Manufacturing Practices Compliance and Inspection Sector staff member who deals with coordination of GMP inspections Marketing Authorisation Holder Out of specification Product Team Leader (for human medicinal products) and Project Manager (for veterinary medicinal products) Product Team Member Quality (for human medicinal products) SOP/INSP/2011, 13-MAY-11 Page 2/7

8. Process map(s)/ flow chart(s) START 1. Receive Draft CTR 2. Review Draft CTR and provide editorial comments to EDQM 3. Receive and file final CTR 4.1 Follow SOP/INSP/2018 OOS results 4. CTR highlights OOS results or GMP issues? GMP Issues 4.2 Forward report to GMP Inspection Coordinator 5. Send CTR to MAH for comments 6. Receive comments on CTR from MAH 7. CTR highlights any other issues? 7.1 Send CTR and MAH Comments to R/CR END 8. Send CTR, MAH comments and Reply Sheet to R/CR 9. Receive Reply Sheet from R/CR and carry out any follow-up actions Continue with Step 10. SOP/INSP/2011, 13-MAY-11 Page 3/7

Continue from Step 9. 10. R/CR requests additional information and/or follow up any action? 10.1 Request additional information and/or follow up any action 11. R/CR requests routine GMP inspection? 11.1 Forward documents to GMP Inspections co-ordinator to follow up. 12. R/CR requests retesting in a future programme? 12.1 Follow SOP/INSP/2010 13. R/CR requests any other action? 13.1 Co-ordinate any other action 14. Close file and file all relevant documents. END SOP/INSP/2011, 13-MAY-11 Page 4/7

9. Procedure Step Action Responsibility 1 Receive draft CTRs from EDQM. EMA receives on an on-going basis the electronic copies of the draft CTRs from EDQM, with the request to provide editorial comments. 2 Review draft CTRs and provide editorial comments to EDQM within two weeks. Save draft CTRs in DREAM under: OperationalUnits/Inspections/Samptest/e.Programmes/Year/ 3_Reports/Draft reports. 3 Receive final CTRs from EDQM. EMA receives on an on-going basis the electronic copies of the final CTRs from EDQM. Save draft CTRs in DREAM under: OperationalUnits/Inspections/Samptest/e.Programmes/Year/ 3_Reports/Final reports. 4 Does CTR highlight OOS results or GMP issues? OOS results: go to Step 4.1 GMP issues: go to Step 4.2 No OOS or GMP issues: go to Step 5 4.1 CTR identifies out of specification results. Follow SOP/INSP/2018 Dealing with reports of defective medicinal Scientific Administrator products. MAH, Rapporteur, Co-Rapporteur, Supervisory Authorities and EMA Product Team Members are informed during the procedure. Go to Step 5. 4.2 CTR identifies GMP issues (that could be dealt by an inspection of the relevant manufacturing site). Forward the report to the P-CI coordinator if manufacturing site is in a third country or to the relevant Supervisory Authority if manufacturing site is in the EEA. Go to Step 5. 5 Send CTR to MAH by Eudralink using the text in the template Template for Eudralink messages, for the transmission of CAP Testing Report to the Marketing Authorisation Holder. Ask the MAH to comment on the content and/or the conclusions of the report. 2 weeks deadline to reply. 6 Receive comments from MAH. Save MAH comments in DREAM under: OperationalUnits/Inspections/Samptest/e.Programmes/Year/ 4_Circulation and follow up. 7 Does CTR highlight any other issues? No: go to Step 7.1 Yes: go to Step 8 7.1 CTR does t highlight any issue. SOP/INSP/2011, 13-MAY-11 Page 5/7

Step Action Responsibility On receipt of the MAH comments (or after the deadline has expired), forward: CTR MAH comments (if any) to the Rapporteurs by Eudralink using the text in the template Template for Eudralink messages, for the transmission of CAP Testing Report to the Rapporteurs. The documents are for information and filing (we do t foresee to receive any comments from Rapporteurs). 2 weeks deadline to reply. On expiry of deadline close the file. 8 CTR highlights other issues (technical, scientific, editorial). On reception of the MAH comments (or after the deadline has expired), forward: CTR MAH comments (if any) Reply Sheet to the Rapporteurs. The Rapporteurs are asked to provide advice in relation to possible follow-up actions (steps 10-13). 4 weeks deadline to reply. 9 Receive Reply Sheet from Rapporteurs and carry out any follow-up action. These can be taken on the basis of the Rapporteurs advice and/or after liaison with PTL/PTMQ (when the R/CR did t provide any response). 10 Rapporteur requests the MAH to provide any additional information and/or to take any follow-up action? No: go to Step 11 Yes: go to Step 10.1 10.1 Contact the MAH to provide additional information and/or to take any follow-up action (e.g. submit a variation, update SOP) MAH to be contacted: directly by the P-CI Or by the PTL/PTQM Continue with step 11. 11 Rapporteur requests the issue(s) highlighted in the CTR to be included in next routine GMP inspection? No: go to Step 12 Yes: go to Step 11.1 11.1 Forward correspondence to P-CI coordinator, with the request to follow-up. Continue with step 12. 12 Rapporteur requests to include product in a future Sampling and Testing Programme? No: go to Step 13 Yes: go to Step 12.1 12.1 Include the product in one of the next years Sampling and Testing SOP/INSP/2011, 13-MAY-11 Page 6/7

Step Action Responsibility Programmes. Follow SOP/INSP/2010. Continue with step 13. 13 Rapporteur requests any other action? No: go to Step 14 Yes: go to Step 13.1 13.1 Organise/co-ordinate the action (e.g. organise ad hoc inspection of the manufacturing site; re-testing of the product as a matter of urgency, meeting with Rapporteurs) and report as appropriate. Continue with step 14. 14 Save all relevant documents in DREAM. Close the file. 10. Records Electronic copies of documents related to each programme are filed in electronic folders in DREAM under: Operational Units/Inspections/Samptest/e.Programmes/YYYY. SOP/INSP/2011, 13-MAY-11 Page 7/7